IQVIA Holdings (IQV) AI Stock Analysis

• Market Cap: $36.86B
• Dividend Yield: N/A
• Average Volume (3M): 1.62M
• Price to Earnings (P/E): 29.7
• Beta (1Y): 0.92
• Revenue Growth: 3.85%
• EPS Growth: -4.74%
• Country: US
• Employees: 89,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 3.00
• Shares Outstanding: 170,300,000
• 10 Day Avg. Volume: 2,033,300
• 30 Day Avg. Volume: 1,621,534
• PEG Ratio: 10.65
• Price to Book (P/B): 5.87
• Price to Sales (P/S): 2.31
• P/FCF Ratio: 16.85
• Enterprise Value/Market Cap: 1.25
• Enterprise Value/Revenue: 2.89
• Enterprise Value/Gross Profit: 8.56
• Enterprise Value/Ebitda: 13.38
• 1Y Price Target: $236.62
• Price Target Upside: 9.31% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15

• Rating: 77 Outperform
• Price Target: $248.00 ▲(14.57% Upside)

IQVIA's strong financial performance and positive earnings call sentiment are the most significant factors driving the overall score. The company's robust cash flow and strategic focus on AI and technology advancements suggest potential for future growth. However, the high P/E ratio and absence of a dividend yield weigh on the valuation, and technical indicators suggest caution due to nearing overbought conditions.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term financial stability.

AI and Technology Advancements

Investing in AI enhances operational efficiency and competitive positioning, potentially leading to improved margins and innovation.

Cash Flow Generation

Strong cash flow generation provides financial flexibility for investments and debt reduction, supporting sustainable growth.

Negative Factors

R&D Solutions Revenue Growth

Slower growth in R&D Solutions may indicate challenges in capturing market share, potentially affecting future revenue streams.

Phase I and Mega Trials Delays

Delays in major trials can impact revenue timelines and client trust, posing risks to long-term project pipelines.

Margin Headwinds

Margin pressures from currency impacts and lower-margin segments could affect profitability, challenging cost management efforts.

IQVIA Holdings Business Overview & Revenue Model

Company Description

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

How the Company Makes Money

IQVIA generates revenue through a combination of service-based contracts and subscription-based solutions. Its key revenue streams include fees from clinical trial management and support services, which involve designing and conducting clinical trials for pharmaceutical and biotechnology companies. Additionally, IQVIA earns revenue from its technology solutions, including data analytics and software platforms that offer insights into healthcare trends and patient populations. Significant partnerships with pharmaceutical companies and healthcare organizations enhance its credibility and market reach, contributing to steady revenue growth. Furthermore, IQVIA's ability to provide integrated solutions across the drug development lifecycle allows it to capture a larger share of the market, driving further earnings.

IQVIA Holdings Financial Statement Overview

Summary

IQVIA Holdings exhibits strong financial performance with consistent revenue growth and improved profitability margins. The significant reduction in leverage enhances financial stability, while robust cash flow generation supports operational flexibility. However, attention to cost management and maintaining liquidity is crucial for sustaining growth.

Income Statement

IQVIA Holdings demonstrates strong revenue growth with a TTM (Trailing-Twelve-Months) revenue increase of 1.3% and consistent annual growth. The gross profit margin remains stable around 34%, while the net profit margin shows improvement, reaching 8.1% in the TTM period. EBIT and EBITDA margins are healthy, indicating efficient operations. However, the slight decline in gross profit margin over time suggests potential cost pressures.

Balance Sheet

The company's debt-to-equity ratio has significantly improved in the TTM period, dropping to 0.39 from over 2 in previous years, indicating reduced leverage and financial risk. Return on equity remains strong at 21.4%, reflecting effective use of equity to generate profits. However, the equity ratio is relatively low, suggesting a higher reliance on debt financing historically.

Cash Flow

IQVIA Holdings shows robust free cash flow growth of 31.3% in the TTM period, indicating strong cash generation capabilities. The operating cash flow to net income ratio is stable, and the free cash flow to net income ratio is high at 94.2%, reflecting efficient cash conversion. However, the operating cash flow coverage ratio has decreased slightly, which could indicate potential liquidity constraints.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.90B	15.40B	14.98B	14.41B	13.87B	11.36B
Gross Profit	5.37B	5.38B	5.24B	5.03B	4.64B	3.86B
EBITDA	3.44B	3.45B	3.26B	2.91B	2.77B	2.08B
Net Income	1.28B	1.37B	1.36B	1.09B	966.00M	279.00M
Balance Sheet
Total Assets	28.73B	26.90B	26.68B	25.34B	24.69B	24.56B
Cash, Cash Equivalents and Short-Term Investments	1.97B	1.84B	1.50B	1.31B	1.48B	1.90B
Total Debt	15.19B	14.16B	13.90B	13.01B	12.44B	12.90B
Total Liabilities	22.44B	20.83B	20.57B	19.57B	18.65B	18.28B
Stockholders Equity	6.16B	6.07B	6.11B	5.76B	6.04B	6.00B
Cash Flow
Free Cash Flow	2.64B	2.11B	1.50B	1.59B	2.30B	1.34B
Operating Cash Flow	2.80B	2.72B	2.15B	2.26B	2.94B	1.96B
Investing Cash Flow	-1.51B	-1.44B	-1.60B	-2.01B	-2.10B	-796.00M
Financing Cash Flow	-1.06B	-878.00M	-382.00M	-329.00M	-1.24B	-217.00M

IQVIA Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 216.46
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IQV, the sentiment is Positive. The current price of 216.46 is above the 20-day moving average (MA) of 210.25, above the 50-day MA of 197.07, and above the 200-day MA of 178.15, indicating a bullish trend. The MACD of 6.58 indicates Positive momentum. The RSI at 64.17 is Neutral, neither overbought nor oversold. The STOCH value of 57.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IQV.

IQVIA Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDP	―	$16.35B	40.59	73.70%	―	13.88%	23.92%
IQV	―	$36.86B	29.72	19.55%	―	3.85%	-4.74%
DHR	―	$151.90B	44.04	6.84%	0.57%	2.22%	-7.60%
TMO	―	$210.04B	32.27	13.16%	0.30%	3.22%	8.26%
DGX	―	$19.57B	20.65	13.69%	1.79%	13.74%	14.87%
ICLR	―	$13.36B	23.23	6.27%	―	-2.46%	-17.89%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

IQVIA Holdings Corporate Events

IQVIA Holdings Reports Strong Q3 2025 Results

IQVIA Holdings Inc. is a global leader in providing clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries, leveraging advanced analytics and AI technologies. In its third-quarter 2025 earnings report, IQVIA announced a revenue increase of 5.2% year-over-year, reaching $4.1 billion, with a GAAP net income of $331 million and an adjusted EBITDA of $949 million. The company also reported a significant free cash flow increase of 35% year-over-year, amounting to $772 million. Key financial highlights include a robust performance in its Research & Development Solutions segment, with quarterly bookings of $2.6 billion and a contracted backlog of $32.4 billion, indicating strong future revenue potential. Additionally, the Technology & Analytics Solutions and Contract Sales & Medical Solutions segments also showed solid growth. Looking forward, IQVIA remains confident in sustaining its growth trajectory, supported by strong demand indicators and a strategic focus on leveraging its comprehensive portfolio of solutions.

IQVIA Holdings: Strong Earnings and Strategic Growth

IQVIA Holdings’ recent earnings call conveyed a positive sentiment, highlighting strong financial performance and record-high free cash flow. The company demonstrated significant growth in net bookings and backlog, despite facing challenges in the R&D Solutions segment and delays in mega trials. IQVIA’s focus on AI and technology advancements underscores its optimism for future efficiencies and growth.

Cenobamate’s Real-World Impact: A New Hope for Focal Epilepsy?

Study Overview: The study titled Observational Cohort Study on Adult Patients With Not-adequately Controlled Focal-onset Seizures Treated With Cenobamate as Early Adjunctive Therapy in a Real-world Setting – FOCUS aims to evaluate the clinical response to cenobamate in adult patients with focal epilepsy in France, Germany, and Spain. The study is significant as it seeks to provide real-world data on the effectiveness of cenobamate for patients whose seizures are not adequately controlled by two or three anti-seizure medications (ASMs).

IQVIA’s Latest Clinical Study Update: A Game Changer in Cardiovascular Treatment?

Study Overview: The study titled ‘A Prospective, Open-Label, Multi-Country, Multicentre, Observational PoSt Market SurvEillance of VIVO ISAR’ aims to assess the safety and performance of the Polymer-Free Sirolimus Eluting Coronary Stent System in patients with coronary artery disease. The key objective is to evaluate clinical outcomes in patients undergoing percutaneous coronary intervention (PCI) with a short dual antiplatelet therapy (DAPT) regimen, highlighting its significance in real-world applications.

IQVIA’s Innovative Approach: The Carry Life UF System Study Update

Study Overview: The Carry Life@ UF System Clinical Study, officially titled ‘A Clinical Study With the Carry Life® UF System in Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients,’ aims to evaluate the effectiveness of the Carry Life UF system in enhancing ultrafiltration in CAPD patients. This study is significant as it could improve treatment outcomes for patients with End Stage Renal Disease by optimizing peritoneal dialysis processes.

IQVIA’s Latest Clinical Study on NOC-110: A Potential Game-Changer for Chronic Cough

Study Overview: The study titled A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults With Refractory or Unexplained Chronic Cough aims to evaluate the effectiveness, safety, and tolerability of NOC-110. This research is significant as it targets adults suffering from chronic coughs that are either unexplained or resistant to existing treatments.

IQVIA’s Latest Clinical Study Update: A New Hope for Peripheral Arterial Disease

IQVIA Holdings (IQV) has recently provided an update on a clinical study titled ‘Prospective, Multi-center, Single-arm Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal Arteries.’ The study aims to evaluate the safety and effectiveness of the SWM-831 device in treating peripheral arterial disease, specifically targeting calcified femoropopliteal arteries. This research is significant as it could offer new treatment options for patients with this condition.

IQVIA and Swedish Orphan Biovitrum’s PNH Study: A Potential Game-Changer for Pegcetacoplan

IQVIA Holdings and Swedish Orphan Biovitrum are collaborating on a clinical study titled ‘A Single Arm, Long-term, Multicentre Observational Study to Evaluate Effectiveness of Pegcetacoplan Under Real World Conditions in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH).’ The study aims to assess the real-world effectiveness of pegcetacoplan, a treatment for PNH, over a period of up to 72 months. This research is significant as it seeks to provide comprehensive data on the long-term impact of pegcetacoplan in a real-world setting.

QUVIVIQ® Pregnancy Registry: Insights into Insomnia Treatment During Pregnancy

Study Overview: The QUVIVIQ® Pregnancy Registry, officially titled ‘Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®,’ aims to explore the effects of QUVIVIQ exposure on pregnancy, neonatal, and infant outcomes. This study is significant as it seeks to provide insights into the safety and implications of using QUVIVIQ, a treatment for insomnia, during pregnancy.

IQVIA Holdings Announces New CFO Appointment

On September 2, 2025, IQVIA Holdings announced the appointment of Michael J. Fedock as Executive Vice President and Chief Financial Officer, effective February 28, 2026. This transition is part of the company’s CFO succession plan, with Fedock succeeding Ronald E. Bruehlman, who will retire and transition to a Senior Advisor role to the CEO. Fedock, with over 25 years of experience in the healthcare industry, has held several senior financial roles within IQVIA since joining in 2016. The transition aims to ensure continuity and support IQVIA’s long-term growth strategy, with Bruehlman having played a crucial role in the company’s transformation and growth since 2011.

The most recent analyst rating on (IQV) stock is a Buy with a $221.00 price target. To see the full list of analyst forecasts on IQVIA Holdings stock, see the IQV Stock Forecast page.